Can omega-3 (polyunsaturated fatty acids) supplements lower Low-Density Lipoprotein (LDL) cholesterol levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Omega-3 Fatty Acid Supplements Do Not Lower LDL Cholesterol and May Actually Raise It

Omega-3 fatty acid supplements are not recommended for lowering LDL cholesterol—they primarily reduce triglycerides but can increase LDL-C levels, particularly formulations containing both EPA and DHA. 1

The Paradoxical Effect on LDL Cholesterol

While omega-3 fatty acids effectively lower triglycerides by 20-50%, the evidence consistently shows a concerning rise in LDL cholesterol with supplementation:

  • Fish oil supplements containing both EPA and DHA raise LDL cholesterol in patients with type 2 diabetes and hypertriglyceridemia, which is a significant concern for cardiovascular risk. 1

  • The American Diabetes Association explicitly warns that "the accompanying rise in plasma LDL cholesterol is of concern" when fish oil supplementation is used for triglyceride lowering. 1

  • If omega-3 supplements are used for triglyceride management, LDL cholesterol levels must be monitored closely due to this adverse effect. 1

Why This Matters for Clinical Practice

The 2021 ACC guidelines make clear that there is no data supporting omega-3 fatty acid dietary supplements for ASCVD risk reduction or to lower triglycerides in primary prevention patients aged 40-75 years without established cardiovascular disease. 1

The Critical Distinction: EPA-Only vs. EPA+DHA Formulations

  • Products containing DHA (docosahexaenoic acid) are responsible for the LDL-C increase, while EPA-only formulations like icosapent ethyl do not raise LDL cholesterol. 2, 3

  • In clinical trials, icosapent ethyl (pure EPA) decreased or did not significantly increase LDL-C levels, whereas omega-3 acid ethyl esters (containing both EPA and DHA) consistently raised LDL-C. 3

  • Over-the-counter fish oil supplements typically contain both EPA and DHA, making them more likely to increase LDL cholesterol compared to prescription EPA-only products. 2

What Actually Lowers LDL Cholesterol

For patients seeking to lower LDL cholesterol specifically, the evidence-based approach is:

  • Statins remain the first-line therapy for LDL-C reduction, with high-intensity statins providing ≥50% LDL-C reduction and proven cardiovascular benefit. 1, 4

  • Dietary modifications including reducing saturated fat to <7% of total calories, limiting cholesterol to <200 mg/day, and eliminating trans fats are foundational. 1, 4

  • Dietary intake of omega-3 fatty acids from fish (not supplements) is encouraged for cardiovascular protection, with recommendations for 2 servings of fatty fish per week. 1

The Role of Omega-3 Supplements in Lipid Management

Omega-3 supplements have a specific, limited role:

  • Prescription omega-3 fatty acids are indicated for severe hypertriglyceridemia (≥500 mg/dL) as adjunctive therapy, not for LDL cholesterol lowering. 4

  • Icosapent ethyl (EPA-only) at 2-4g daily can be considered for patients with triglycerides ≥150 mg/dL on maximally tolerated statin therapy with established cardiovascular disease or diabetes with additional risk factors. 4

  • The primary benefit is triglyceride reduction (20-50% decrease) and cardiovascular event reduction (25% in the REDUCE-IT trial), not LDL-C lowering. 4, 5

Common Pitfalls to Avoid

  • Do not recommend omega-3 supplements as a strategy to lower LDL cholesterol—this is not supported by evidence and may worsen lipid profiles. 1

  • Do not substitute over-the-counter fish oil for prescription omega-3 formulations when triglyceride lowering is needed, as supplements lack standardization and may contain contaminants. 2

  • Do not ignore the LDL-C increase that occurs with EPA+DHA formulations—this requires monitoring and may necessitate intensification of statin therapy. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Overview of omega-3 Fatty Acid therapies.

P & T : a peer-reviewed journal for formulary management, 2013

Research

Comparing the Impact of Prescription Omega-3 Fatty Acid Products on Low-Density Lipoprotein Cholesterol.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2018

Guideline

Hypertriglyceridemia Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.